Research & Development
-
Profile
Three years after an FDA rejection, DBV sees a path for its peanut patch
Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.
By Karissa Waddick • Sept. 22, 2023 -
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
By Julia Himmel • Sept. 19, 2023 -
Endangered horseshoe crabs could lead the charge in pharma’s animal-free future
An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.
By Kelly Bilodeau • Sept. 18, 2023 -
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
Q&A
In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
By Michael Gibney • Sept. 14, 2023 -
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
By Meagan Parrish • Sept. 13, 2023 -
Biotech Spotlight
Immuneering takes aim at cancer’s ‘superhighway’
After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.
By Kelly Bilodeau • Sept. 11, 2023 -
Profile
Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery
Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.
By Alexandra Pecci • Sept. 6, 2023 -
Hope sputters for emerging anti-TIGIT drug class
Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.
By Kelly Bilodeau • Sept. 5, 2023 -
Sponsored by Advarra
4 modernized functions every sponsor needs for study startup
Explore four modern tech capabilities designed to help decrease cycle times, improve processes and compliance and mitigate site burdens.
By Stuart Cotter, VP Product Innovation and Strategy, Advarra • Sept. 5, 2023 -
A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?
Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.
By Meagan Parrish • Sept. 1, 2023 -
Medicare named the first 10 drugs up for negotiation. Now what?
The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.
By Karissa Waddick • Aug. 30, 2023 -
Q&A // Biotech Spotlight
‘We need to do better:’ A biotech CEO on standing apart from the crowd
The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.
By Michael Gibney • Aug. 29, 2023 -
Why pharma isn’t done tackling migraines
In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options.
By Kelly Bilodeau • Aug. 28, 2023 -
‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax
New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.
By Michael Gibney • Aug. 24, 2023 -
Henrietta Lacks’ immortal cells put biopharma profits under a microscope
The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.
By Michael Gibney • Aug. 23, 2023 -
Biotech Spotlight
Brii Biosciences aims to come up big where Sage and Biogen fell short
The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.
By Kelly Bilodeau • Aug. 21, 2023 -
Behind Flagship Pioneering’s triumphs and tribulations
From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.
By Karissa Waddick • Aug. 18, 2023 -
How an AstraZeneca exec is leading the charge in the next immuno-oncology era
The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.
By Michael Gibney • Aug. 17, 2023 -
Podcast
Woman of the Week: Novartis’ Christy Siegel
The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.
By Taren Grom and Meagan Parrish • Aug. 15, 2023 -
Q&A // Biotech Spotlight
Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine
The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.
By Kelly Bilodeau • Aug. 14, 2023 -
What pharma companies are getting wrong about drug repositioning
Children’s Tumor Foundation president Annette Bakker is working to teach the industry the crucial difference between drug repurposing and drug repositioning.
By Alexandra Pecci • Aug. 9, 2023 -
Podcast
Woman of the Week: AmyriAD Therapeutics’ Sharon Rogers
The CEO of the Alzheimer’s-focused biotech discusses its phase 3-ready candidate and what it could contribute to the bustling field.
By Taren Grom and Meagan Parrish • Aug. 9, 2023 -
In the era of blockbuster obesity drugs, a personalized approach could boost outcomes
Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.
By Michael Gibney • Aug. 8, 2023 -
Pharma’s rocky love affair with oxytocin
Although research on using oxytocin as a drug has varied, Tonix Pharmaceuticals is banking on the “love hormone” to treat migraines, anxiety and more.
By Kelly Bilodeau • Aug. 7, 2023